The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Subscribe To Our Newsletter & Stay Updated
